香港股市 已收市

Biodexa Pharmaceuticals Plc (5MP.F)

Frankfurt - Frankfurt 延遲價格。貨幣為 EUR。
加入追蹤清單
0.7750+0.0500 (+6.90%)
收市:08:00AM CET

Biodexa Pharmaceuticals Plc

1 Caspian Point
Caspian Way
Cardiff CF10 4DQ
United Kingdom
44 29 2048 0180
https://www.biodexapharma.com

版塊Healthcare
行業Biotechnology
全職員工27

高階主管

名稱頭銜支付行使價出生年份
Mr. Stephen A. StampCEO, CFO, Company Secretary & Director293.78k1962
Dr. Dmitry Zamoryakhin M.D.Chief Scientific Officer & Chief Medical Officer277.88k1980
Dr. Daniel Palmer MBA, Ph.D.Vice President of Technology
Ms. Nicola TuckwellVP & Head of Clinical Operations
Ms. Fiona SharpGroup Financial Controller
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

公司管治

截至 無 止,Biodexa Pharmaceuticals Plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。